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Evidence-based answer
Depot	medroxyprogesterone	acetate	
(DMPA;	Depo-Provera)	and	the	
combination	contraceptive	vaginal	ring	
(Nuvaring)	are	most	effective	for	obese	
women	because	they	don’t	appear	to	
be	affected	by	body	weight	(strength	of	
recommendation	[sor]:	B,	consistent	
cohort	studies).	
	 on	the	other	hand,	women	using	the	
combination	contraceptive	patch	(ortho	
evra)	who	weigh	≥90	kg	may	experience	
decreased	contraceptive	efficacy	(sor:	A,	
meta-analysis).	obese	women	using	oral	
contraceptives	may	also	have	an	increased	
risk	of	pregnancy	(sor:	B,	inconsistent	
cohort	studies).	Data	are	not	available	on	
the	levonorgestrel	intrauterine	system’s	
(Mirena)	efficacy	in	obese	women.
Clinical commentary
Obese women may have  
higher rates of pregnancy with OCs
This	answer	shows	that	we	need	to	
provide	more	guidance	to	obese	patients	
during	contraceptive	counseling.	In	
our	practice,	we	may	have	to	develop	
contraceptive	information	sheets	for	
overweight	women.	
	 I	don’t	think	this	will	prevent	me	from	
prescribing	oral	contraceptives	for	obese	
women,	but	it	will	cause	me	to	pause	a	bit.	
This	question	makes	me	wonder	whether	
official	recommendations	in	other	drug	
classes	for	obese	patients	are	coming	in	
the	near	future.
Ronald Januchowski, DO
spartanburg	regional	Family	Medicine	Program,	
spartanburg,	sC
z Evidence summary
There is a theoretical risk of decreased 
hormonal contraceptive efficacy for 
obese women (defined as those having 
a body-mass index [BMI] ≥30 kg/m2) 
due to increased metabolism of the 
hormones resulting in lower serum 
levels. With the growing epidemic of 
obesity, concern over the efficacy of 
hormonal contraception has grown. 
At this time, however, only a few pub-
lished studies evaluating contraception 
have specifically examined the effect of 
body weight on efficacy.
Pregnancy risk doubled  
among heavier patients on OCs 
Some studies have shown a possible as-
sociation between obesity and higher 
rates of pregnancy among women using 
oral contraceptives for birth control. 
One retrospective cohort analysis 
found that women weighing >70.5 kg had 
an increased risk of pregnancy compared 
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Obese women 
using OCs and 
the contraceptive 
patch have  
an increased risk 
of pregnancy
with women of lower weight (relative 
risk [RR]=1.6; 95% confidence interval 
[CI], 1.1–2.4), after controlling for par-
ity.1 Pill compliance was not accounted 
for in this study. A follow-up case-control 
study demonstrated that the risk of preg-
nancy for consistent pill users doubled 
for women with a BMI >27.3 (odds ratio 
[OR]=2.17; 95% CI, 1.38–3.41); results 
were similar for those with a BMI >32.2 
(OR=2.2; 95% CI, 1.18–4.20).2 
Another large cohort study did not 
find any association between failure of 
the oral contraceptive pill or progestin-
only pill and obesity; however, the total 
number of pregnancies among obese 
women was too small to achieve statis-
tical significance.3 In a randomized trial 
studying the efficacy of an extended-
cycle oral contraceptive (Seasonale), 
no woman weighing >90 kg became 
pregnant.4
When it comes to the combination 
contraceptive patch, the data show a 
significant association between baseline 
body weight and pregnancy. In an anal-
ysis of pooled data, 5 of 15 pregnan-
cies occurred in a subgroup of women 
with a baseline body weight ≥90 kg. 
Less than 3% of the study population 
weighed more than 90 kg. Specific data 
for this subgroup were not presented in 
the study results, so measures of effect 
cannot be calculated. The mechanism of 
the decreased efficacy of the combined 
contraceptive patch for obese women is 
unclear.5
DMPA and vaginal ring may be  
a better option for obese women 
Data suggest that increased body weight 
does not decrease the efficacy of DMPA. 
In 2 large open-label studies, no preg-
nancies were observed, regardless of 
BMI.6 Similarly, the efficacy of the con-
traceptive vaginal ring does not appear 
to be affected by body weight, but the 
mean BMI in intent-to-treat population 
studies was only 22.9 ± 2.9.7
A secondary analysis of the con-
traceptive vaginal ring efficacy trials 
did not show an increased pregnancy 
rate among heavier women.8 Of note: 
A higher body weight appeared to be 
associated with increased likelihood of 
ovulation using the contraceptive vagi-
nal ring, though it did not lead to any 
pregnancies in a multicenter study.9
The data on the levonorgestrel intra-
uterine system do not examine weight 
and efficacy.10
Recommendations from others 
The World Health Organization gen-
erally recommends hormonal contra-
ceptives as safe for obese women. The 
group acknowledges that data are lim-
ited regarding effectiveness of oral con-
traceptives, and efficacy may be lower 
for the combination contraceptive patch 
when used by obese women.11
The American College of Obstetrics 
and Gynecology (ACOG) suggests that 
despite the possibility of higher failure 
rates with oral and transdermal contra-
ception, motivated obese women should 
still be encouraged to use these methods 
preferentially over known less effec-
tive methods.12 In addition, ACOG also 
notes that no higher rates of pregnancy 
are observed among overweight women 
using DMPA.  n
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